ICAM2 and cholangiocarcinoma: Although more than 23% of CCA patients exhibited down-regulation of FUCA1, ICAM2, MDM2, p21, p53, or PAI-1 expression, there is no correlation between expression of these genes and various clinicopathological parameters.